In this report, Morris et al describe three patients with refractory malignant disease, who died of an ARDS-like syndrome within the first few weeks after autologous stem cell transplantation (autoSCT). These patients were found to have increased pretransplant serum levels of C-reactive protein (CRP), as compared with a group of 21 patients who survived the transplant procedure. Post transplant levels of CRP did not differ significantly between groups. The authors found no additional value in measuring cytokine levels, including IL-6 and TNF-alpha, either preor post transplant.
The observation of Morris et al is based on a low number of patients, which prompts caution with respect to the value of the statistical analysis. For example, post transplant CRP levels in patients developing transplant-related mortality (TRM þ ) are clearly higher (medians of 185 vs 30 mg/l), but the number of patients is too low to show the difference. Also, the highest levels are included in the analysis, whereas the duration of elevated CRP and cytokine levels is not specified. In our experience, sustained increases are more relevant than short peak levels. Nevertheless, the findings of Morris et al suggest that high CRP levels before transplant may be helpful in identifying patients at risk of TRM after autoSCT.
In the setting of allogeneic bone marrow transplantation (alloBMT) and using standard conditioning, we recently demonstrated that the degree of systemic inflammation within the first 5-10 days after alloBMT is a strong and independent risk factor for early as well as late TRM. 1, 2 Our interpretation is that the conditioning regimen and some infections trigger a variable systemic inflammatory response reaction (SIRR) in each patient. The magnitude of the SIRR is determined by prior cytotoxic exposure as well as genetic factors. In sensitive patients (735% in our series), a severe SIRR will develop, as reflected by high and sustained (several days) increases of CRP and proinflammatory cytokines, including IL-6, IL-8 and TNF-alpha. These patients are at a risk of severe organ damage, and are likely to experience alloreactivity leading to graft-versushost disease. Direct and indirect consequences of these events will lead to increased early as well as late TRM.
Although we did not measure CRP before transplant systematically, the data of Morris et al are consistent with our findings in alloBMT, at least with respect to early TRM. They further support the basis to consider close monitoring and early (eg pre-emptive) anti-inflammatory treatment in patients with high CRP levels shortly after transplant, provided that the appropriate anti-infection measures have been taken. Whether high levels of CRP prior to transplant represent an important and independent risk factor for TRM requires further study in autologous as well as allogeneic settings.
